Asthma
Conditions
Keywords
Exacerbations
Brief summary
The purpose of this study is to investigate exacerbations in severe asthma with regard to symptoms, lung function, aetiology and biomarkers.
Detailed description
Patients will be recruited from the Severe Asthma Clinics at Royal Brompton Hospital. At the first visit the investigators will enrol and characterise patients. This will involve asking patients to keep a diary record of PEFR(Peak Expiratory Flow Rate), spirometry, symptom scores, use of beta-agonist reliever and other treatments for 2 weeks. Bloods tests will be taken for markers of systemic inflammation. Markers of oxidative stress will be measured in blood, exhaled breath condensate (EBC) and urine: malondialdehyde (MDA) and 8-isoprostanes. Nitric oxide (NO) levels in exhaled breath will be measured measured twice daily for 2 weeks using a portable hand-held NO meter. If spontaneous sputum is not available, sputum will be induced using ultrasonic nebulization of isotonic saline. Profile of inflammatory cells, cytokines in supernatants, bacteriological culture and microbiome analysis will be measured in the sputum. Patients will be observed over 12 months during which time the number of exacerbations will be recorded on basis of objective measures with evaluation of ACQ (Asthma Control Questionnaire), daily morning and evening PEF (Peak Expiratory Flow). At the earliest onset of exacerbation, the patient will be requested to contact the Asthma Research Unit. Patients will then be asked to attend the laboratory where similar tests to the first visit will be performed. For other exacerbations not studied, the patient will be asked to keep a detailed diary record of symptoms with severity scoring and spirometric and PEF measurements (Exacerbation Diary) over a period of 2 weeks after onset of exacerbation. As patients with severe asthma are usually very well experienced in what the symptoms of exacerbations are, they will therefore be asked to recognise their own exacerbations. Each patient has their own way of recognising an exacerbation and the investigators will discuss this with each patient and try and establish whether an earlier warning signal is possible. Patients will be asked to record their symptoms and lung function as soon as they feel the onset of an exacerbation, since exacerbations are recognised by the patient as events that are 'clinically identified by being outside the patient's usual range of day-to-day variation'. The patient will receive or administer treatments for the exacerbation as usual without interference from the Research Team except for starting any antibiotic therapies, which will be started (if prescribed) as soon as the visit studies have been completed. Those who have been hospitalized will not be studied, and only those who can attend the Clinical Research Unit will be studied.
Interventions
DIAGNOSTIC_TESTFEV1
Participants have FEV1 test
Sponsors
Royal Brompton & Harefield NHS Foundation Trust
Imperial College London
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* All patients must be able to give informed consent. The definition of severe asthma will be on the basis of * Uncontrolled asthma: three or more of the following features present in any week in the previous 4 weeks: * Daytime symptoms more than twice per week * Any limitation of activities * Nocturnal symptoms once or more per week * Need for reliever treatment more than twice per week * Pre bronchodilator FEV1 \<80% predicted or personal best OR * Frequent severe exacerbations (≥2 per year) OR * Require prescription of daily or alternate day oral corticosteroids (OCS) to achieve asthma control despite the prescription of high dose inhaled corticosteroids (\>1000mcg fluticasone propionate daily or equivalent) or maintenance oral corticosteroids plus a long acting beta agonist or one other controller medication (for example anti-cholinergics, leukotriene receptor antagonists or theophylline).
Exclusion criteria
* • Current smoker, or Ex-smoker with a \>10 year pack history or having smoked within the past 6 months * Significant alternative diagnoses that may mimic or complicate asthma, in particular dysfunctional breathing, panic attacks, and overt psychosocial problems (if these are thought to be the major problem rather than in addition to severe asthma) * Significant other primary pulmonary disorders in particular pulmonary embolism, pulmonary hypertension, interstitial lung disease and lung cancer * Subjects with emphysema and bronchiectasis should only be excluded if this is thought to be the major pulmonary disorder rather than in addition to severe asthma * Diagnosis or current investigation of occupational asthma * Any subjects currently participating, or having participated within 3 months of the first dose in a study using a new molecular entity, or the first dose in any other study investigating drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent Predicted FEV1 | Baseline Visit, 12 months | From date of screening visit until date of first asthma exacerbation visit Percent predicted Forced Expiratory Volume in First Second |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PCR for Respiratory Viruses | Baseline Visit, 12 months | nasopharyngeal swabs |
| Sputum Microbiome | Baseline Visit, 12 months | — |
| Corticosteroid Insensitivity in Peripheral Blood Mononuclear Cells | Baseline Visit, 12 months | — |
| Sputum Analysis | From baseline visit and 12 months | Eosinophils as percentage of total count |
| Markers of Oxidative Stress in Urine | Baseline Visit, 12 months | malondialdehyde (MDA) |
| Exhaled Breath Condensate | Baseline Visit, 12 months | pH and free Iron |
| Exhaled Hydrogen Sulphide | Baseline Visit, 12 months | — |
| Exhaled Nitric Oxide | Baseline Visit, 12 months | — |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Severe Asthma Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines | 25 |
| Total | 25 |
Baseline characteristics
| Characteristic | Severe Asthma | — |
|---|---|---|
| Age, Continuous | 55.9 years STANDARD_DEVIATION 11.5 | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Region of Enrollment United Kingdom | 25 participants | — |
| Sex: Female, Male Female | 17 Participants | — |
| Sex: Female, Male Male | 8 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 25 |
| other Total, other adverse events | 0 / 25 |
| serious Total, serious adverse events | 0 / 25 |
Outcome results
Primary
Percent Predicted FEV1
From date of screening visit until date of first asthma exacerbation visit Percent predicted Forced Expiratory Volume in First Second
Time frame: Baseline Visit, 12 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Severe Asthma | Percent Predicted FEV1 | baseline | 58.6 % of predicted value | Standard Deviation 20.4 |
| Severe Asthma | Percent Predicted FEV1 | During exacerbation | 56.3 % of predicted value | Standard Deviation 22.2 |
Comparison: Baseline versus during exacerbation.p-value: 0.745t-test, 2 sided
Secondary
Corticosteroid Insensitivity in Peripheral Blood Mononuclear Cells
Time frame: Baseline Visit, 12 months
Population: No data collected
Secondary
Exhaled Breath Condensate
pH and free Iron
Time frame: Baseline Visit, 12 months
Population: No data collected
Secondary
Exhaled Hydrogen Sulphide
Time frame: Baseline Visit, 12 months
Population: Data were not collected
Secondary
Exhaled Nitric Oxide
Time frame: Baseline Visit, 12 months
Population: Data were not collected
Secondary
Markers of Oxidative Stress in Urine
8-isoprostanes
Time frame: Baseline Visit, 12 months
Secondary
Markers of Oxidative Stress in Urine
malondialdehyde (MDA)
Time frame: Baseline Visit, 12 months
Secondary
PCR for Respiratory Viruses
nasopharyngeal swabs
Time frame: Baseline Visit, 12 months
Population: No data collected
Secondary
Sputum Analysis
Eosinophils as percentage of total count
Time frame: From baseline visit and 12 months
Population: Severe asthma at baseline
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Severe Asthma | Sputum Analysis | Baseline | 10.9 Percentage of total sputum counts | Standard Deviation 30.6 |
| Severe Asthma | Sputum Analysis | At exacerbation | 4.47 Percentage of total sputum counts | Standard Deviation 9.47 |
p-value: 0.326t-test, 2 sided
Secondary
Sputum Microbiome
Time frame: Baseline Visit, 12 months
Population: No data collected